<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="501">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100344</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.114322</org_study_id>
    <nct_id>NCT03100344</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of Nemolizumab in Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving Topical Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy of multiple subcutaneous dose of nemolizumab
      administrated concomitantly with Topical Corticosteroids, in moderate to severe atopic
      dermatitis subjects with severe pruritus who were not adequately controlled with topical
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in EASI (Eczema Area and Severity Index)</measure>
    <time_frame>From Baseline to 24 weeks</time_frame>
    <description>Investigator evaluation of the EASI during the subject on site visit</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nemolizumab (low dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nemolizumab (medium dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nemolizumab (high dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nemolizumab placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemolizumab</intervention_name>
    <description>Injection every for 4 weeks during 24 weeks (last injection at week 20)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection every for 4 weeks during 24 weeks (last injection at week 20)</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects ≥ 18 years (or legal age when higher)

          -  Chronic AD, that has been present for at least 2 years before the visit

          -  Eczema Area and Severity Index (EASI) score ≥12

          -  IGA score ≥ 3

          -  AD involvement ≥ 10% of Body Surface Area (BSA)

          -  Severe pruritus on at least 3 of the last 7 days before the visit

          -  Documented recent history (within 6 months before the visit) of inadequate response
             to topical medications

          -  Female subjects must fulfill one of the criteria below:

          -  Female subjects of non-childbearing potential

          -  Female subjects of childbearing potential who agree to a true abstinence or to use an
             effective or highly effective method of contraception throughout the clinical trial
             and for 120 days after the last study drug administration

        Exclusion Criteria:

          -  Body weight &lt; 45 kg

          -  subjects with a medical history of asthma requiring hospitalization in the last 12
             months before screening visit and/or whose asthma has not been well-controlled during
             the last 3 months before the screening visit and/or Peak Expiratory Flow (PEF) &lt;80%
             of the predicted value

          -  Cutaneous bacterial or viral infection within 1 week before the screening visit or
             during the run-in period

          -  Infection requiring treatment with oral or parenteral antibiotics, antivirals,
             antiparasitics or antifungals within 1 week before the screening visit or during the
             run-in period

          -  Requiring rescue therapy during the run-in period, or expected to require rescue
             shortly following the baseline visit

          -  Positive serology results (hepatitis B surface antigen [HBsAg] or hepatitis B core
             antibody [HBcAb], hepatitis C antibody or Human Immunodeficiency virus [HIV]
             antibody) at the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Galderma</last_name>
    <email>frnceclinicaltrials@galderma.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>March 29, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
